Total Diversity’s mission is to establish sustainability of diversity in clinical trials and make a difference in quality of life for all individuals. Hear from Dr. Jerome Adams, TOTAL’s Chairman of the Board and former US Surgeon General, about how TOTAL is working to achieve this mission.
The clinical research industry remains highly competitive in attracting potential study volunteers to participate in trials. However, much of the focus still goes into study start up activities pushing recruitment planning to the back burner.
Stay ahead of the curve and partner with a CRO that is known for their site selection and enrollment expertise. Total Diversity Clinical Trial Management and successful study results are a click away.
Diana L. Foster, Ph.D
CEO and Chief Diversity Officer for TOTAL Diversity Clinical Trial Management
Diana L. Foster, Ph.D., is the CEO and Chief Diversity Officer for TOTAL Diversity Clinical Trial Management, a full-service Diversity Organization whose mission is to enhance diversity and inclusion in clinical research trials. Foster has served as the Vice President of Diversity, Equity, and Inclusion for the Society of Clinical Research Sites (SCRS) since 2016. She also held a position as the Vice President of Strategy and Development for SCRS originating programs such as the Global Impact Partner Programs and many other industry supported initiatives.
Foster is a thought-leader and sought-after expert in diversity and clinical site best practices. She is the author of the Diversity Site Assessment Tool and has published numerous research papers on the topic. Over the past two decades, she has addressed audiences across the world, published multiple papers and articles, and written five authoritative industry books including Global Issues in Patient Recruitment and Retention.
Jerome Adams, M.D.
Chairman of the Board for TOTAL Diversity Clinical Trial Management
Dr. Adams also currently serves as Executive Director of Health Equity Initiatives at Purdue University. He formerly served as the 20th United States Surgeon General and as a member of the President’s COVID-19 task force, where he was at the forefront of America’s most pressing health challenges throughout the pandemic, including working with companies to increase diversity in vaccine trials.
As the Chairman of the Board for TOTAL Diversity, Dr. Adams provides his in-depth knowledge of patient perspectives and industry views on diversity to create sustainable solutions and best practices to establish more diverse representation in clinical trials.